GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Inc (FRA:1D5A) » Definitions » EPS without NRI

PLx Pharma (FRA:1D5A) EPS without NRI : €-1.41 (TTM As of Sep. 2022)


View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma EPS without NRI?

PLx Pharma's earnings per share without non-recurring items for the three months ended in Sep. 2022 was €0.00. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2022 was €-1.41.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for PLx Pharma's EPS without NRI or its related term are showing as below:

FRA:1D5A's 3-Year EPS without NRI Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 9.2
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

PLx Pharma's EPS (Diluted) for the three months ended in Sep. 2022 was €0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was €-1.41.

PLx Pharma's EPS (Basic) for the three months ended in Sep. 2022 was €0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2022 was €-0.67.


PLx Pharma EPS without NRI Historical Data

The historical data trend for PLx Pharma's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PLx Pharma EPS without NRI Chart

PLx Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.85 0.09 -3.46 -1.43 -1.82

PLx Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.68 -0.65 -0.35 -0.41 -

Competitive Comparison of PLx Pharma's EPS without NRI

For the Drug Manufacturers - Specialty & Generic subindustry, PLx Pharma's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PLx Pharma's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PLx Pharma's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where PLx Pharma's PE Ratio without NRI falls into.



PLx Pharma EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PLx Pharma  (FRA:1D5A) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


PLx Pharma EPS without NRI Related Terms

Thank you for viewing the detailed overview of PLx Pharma's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


PLx Pharma (FRA:1D5A) Business Description

Traded in Other Exchanges
N/A
Address
8 The Green, Suite 11895, Dover, DE, USA, 19901
PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.

PLx Pharma (FRA:1D5A) Headlines

No Headlines